Collins Helen Louise sold $219K of ELVN
Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $43.80 ($42.83–$44.74, $0.22M total) across 3 trades on 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CMO’s open-market sale totaling $219,016.85 across three trades at ~$42.83–$44.74, with holdings after the sale of 25,000 shares.
Market read
This provides a transparent datapoint on insider selling, but it is not a fundamental catalyst by itself.
What to watch
Traders may over-weight insider sales; the key is whether there are concurrent fundamental catalysts (trial/regulatory/financing) not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for Enliven Therapeutics (ELVN).
Ticker impact
Enliven Therapeutics’ chief medical officer Helen Louise Collins sold about $219K of ELVN shares via an open-market sale under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and short-lived.
The filing is a disclosed insider sale (S) with a pre-arranged 10b5-1 plan, and the transaction size is modest relative to typical large-cap trading flows.
Market effects
Minimal sector read-through; this is company-specific insider activity rather than clinical/regulatory or financing news.
None.
None.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish fundamentals.
Key entities
- issuerEnliven Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (ELVN).
- insiderCollins Helen Louise
Chief Medical Officer who sold 5,000 shares under a pre-arranged 10b5-1 plan.
